Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia DIAGNOSIS IN ONCOLOGY

Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Chemotherapy, Biological Therapy DIAGNOSIS IN ONCOLOGY Source Type: research

Related Links:

Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
Source: Clinical Chemistry and Laboratory Medicine - Category: Laboratory Medicine Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Leukemia, Published online: 20 February 2020; doi:10.1038/s41375-020-0771-7Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia
Source: Leukemia - Category: Hematology Authors: Source Type: research
AbstractPurpose of ReviewOral tyrosine kinase inhibitors have revolutionized the treatment of chronic myelogenous leukemia, with many patients achieving major clinical and molecular responses without complications. While typically well-tolerated, clinical experience with tyrosine kinase inhibitors (particularly those of the second and third generations) has highlighted unanticipated associations with serious non-cancer adverse effects on various organs, particularly the cardiovascular system.Recent FindingsHerein, we review the current literature surrounding the major cardiovascular toxicities of BCR-ABL1 tyrosine kinase i...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Leukemia, Published online: 19 February 2020; doi:10.1038/s41375-020-0751-yAberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia
Source: Leukemia - Category: Hematology Authors: Source Type: research
In conclusion, the results of the present study showed that the abrogation of PI3K using BKM120 might be a befitting approach in CML treatment, either as a single agent or in a combined-modal strategy; however, further evaluations including clinical trials and in vivo investigations are demanded to ascertain the safety and the efficacy of the inhibitor in treatment strategies. This article is protected by copyright. All rights reserved. PMID: 32068318 [PubMed - as supplied by publisher]
Source: Cell Biology International - Category: Cytology Authors: Tags: Cell Biol Int Source Type: research
T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface. Because expression of the aberrant target protein is exclusive to malignant cells, immunotherapy directed against neoantigens should avoid “on-target, off-tumor” toxicity. The efficacy of neoantigen vaccines in melanoma and glioblastoma and of adoptive transfer of neoantigen-specific T cells in epithelial tumors indicates that neoantigens are valid therapeutic targets. Improvements in sequencing tec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 12 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): O.V. Lazareva, A.G. Turkina, E.Yu Chelysheva, A.A. Kulikovsky, M.A. Galayko, O.M. Senderova, V.M. Pepeliaeva, S.V. Meresiy, A.S. Luchinin, G.I. Milutina, L.V. Gavrilova, L.B. Avdeeva, E.B. Dasheeva, O.Yu Vinogradova, H.L. Julhakyan, S.M. KulikovIntroductionRussia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016).ObjectiveTo analyze the mortality in the Russian cohort of patients (pts) with new...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Putri A, Rinaldi I, Louisa M, Koesnoe S Abstract Chronic myeloid leukemia (CML) is a clonal haemopoietic stem cell disorders with reciprocal translocation in chromosome 9 (ch9) and 22 (ch22) which cause the fusion of Break cluster region-Abelson murine leukemia (BCR-ABL) oncogene. This fusion will activate tyrosine kinase. Imatinib mesylate is the first tyrosine kinase inhibitor (TKI), which could change the prognosis of CML patients. However, there is a resistance to TKI's, and based on transcriptomic study, increase expression of gen signal transducer and activator of transcription (STAT) 5A and runt-rel...
Source: Acta medica Indonesiana - Category: Internal Medicine Tags: Acta Med Indones Source Type: research
Russia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Current Trial Report Source Type: research
More News: Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Liver | Liver Transplant | Transplants | Urology & Nephrology